BCL2L1_pLX307 Citations (2)

Originally described in: Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in beta-Catenin-Active Cancers.
Rosenbluh J, Mercer J, Shrestha Y, Oliver R, Tamayo P, Doench JG, Tirosh I, Piccioni F, Hartenian E, Horn H, Fagbami L, Root DE, Jaffe J, Lage K, Boehm JS, Hahn WC Cell Syst. 2016 Sep 28;3(3):302-316.e4. doi: 10.1016/j.cels.2016.09.001. PubMed Journal

---

Articles Citing BCL2L1_pLX307

Articles
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. Nardi F, Perurena N, Schade AE, Li ZH, Ngo K, Ivanova EV, Saldanha A, Li C, Gokhale PC, Hata AN, Barbie DA, Paweletz CP, Janne PA, Cichowski K. J Clin Invest. 2023 Aug 15;133(16):e167651. doi: 10.1172/JCI167651. PubMed
Multidimensional, integrative profiling identifies BCL2L1 methylation as a predictor of MCL1 dependency in pediatric malignancies. Adjumain S, Daniel P, Sun CX, Bradshaw G, Chew NJ, Tsui V, Lee H, Loi M, Zhukova N, Habarakada D, Yoel A, Vaghjiani VG, Game S, Ludlow LE, Neeman N, Sweet-Cordero EA, Eisenstat DD, Cain JE, Firestein R. JCI Insight. 2025 Jan 23;10(2):e184601. doi: 10.1172/jci.insight.184601. PubMed

If you have published an article using this material, please email us at to have your article added to this page.